Document is current

Article History

Received: 19 August 2021

Accepted: 20 September 2021

First Online: 9 November 2021

Declarations

:

: The study was approved by the Institutional Review Board (IRB) at Birmingham (#1605), St. Louis, and Philadelphia VA medical centers (each study site’s IRB) also reviewed and approved the study. All investigations were conducted in conformity with ethical principles of research.

: Not applicable

: There are no financial conflicts related directly to this study JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in TPT Global Tech, Vaxart pharmaceuticals and Charlotte’s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking, and Moderna pharmaceuticals. JAS is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 8 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is the chair of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee.Drs. Baker, Richman, and Shaneyfelt have no financial conflicts.Dr. Eisen has received research support from Bristol Myers Squibb.Dr. Joseph has received research support from Bristol Myers Squibb.Dr. Saag has received research support from Horizon, Sobi, and Shanton and consulting fees from Arthrosi, Atom Bioscience, Horizon, Inflazome, L. G. Pharma, Mallinckrodt, Takeda, and Sobi pharmaceuticals.